Latest in Cardiology from ACC.org

• CathPCI Registry Findings: PCI For Stent Thrombosis, AKI Risk and SDD, More
  Recent studies informed by data from ACC's CathPCI Registry explore trends in PCI for stent thrombosis; contrast media dosing during PCI; acute kidney injury (AKI) and same-day discharge (SDD); and disparities in use of atherectomy and intravascular lithotripsy (IVL) during PCI.
• ACCEL Lite: Cardiovascular-Kidney Therapies in CKD
  In this interview, Allen J. Taylor, MD, FACC and Janani Rangaswami, MD examine “Cardiovascular-Kidney Therapies in CKD”.
• Pre-Hospital Glycoprotein IIb/IIIa Inhibition With Zalunfiban in STEMI
  The CELEBRATE (CeleCor Blinded Randomized Trial in ST-Elevation Myocardial Infarction) trial was a phase 3, multicenter, double-blind, placebo-controlled study that evaluated the efficacy and safety of a single subcutaneous injection of zalunfiban (CeleCor Therapeutics), a novel glycoprotein IIb/IIIa inhibitor...
• ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia
  The new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]).
• DANCAVAS: Severe Aortic, Iliac Calcification Associated With Higher Risk of Aortic Events, MALEs
  Severe aortic and iliac calcification was associated with a significantly higher risk of major adverse limb events (MALEs) and aortic events, according to a prospective cohort study from the DANCAVAS trials published March 2 in Circulation. These results suggest that quantifying aortic calcification may provide valuable prognostic information and improve the risk stratification in patients […]